ライフサイエンスコーパス: regurgitation

1 lesion with moderate/severe pulmonary valve regurgitation).

2 ting grade III/IV restrictive DD with mitral regurgitation.

3 e thrombosis, and management of paravalvular regurgitation.

4 valve system in patients with severe mitral regurgitation.

5 ngoing clinical trials for functional mitral regurgitation.

6 r FQs increase the risk of aortic and mitral regurgitation.

7 sertions, or moderate or severe paravalvular regurgitation.

8 ular dilation and dysfunction, and tricuspid regurgitation.

9 aiming to treat patients with severe mitral regurgitation.

10 h heart failure and 3 to 4+ secondary mitral regurgitation.

11 valve repair system, for reducing tricuspid regurgitation.

12 branch block morphology, without significant regurgitation.

13 art failure and symptomatic secondary mitral regurgitation.

14 m, and aortic valve focal thickening and any regurgitation.

15 ystolic or diastolic dysfunction, and aortic regurgitation.

16 in Yorkshire swine by inducing severe mitral regurgitation.

17 lung disease, dialysis, and severe tricuspid regurgitation.

18 rum is associated with higher risk of mitral regurgitation.

19 positioning and reduction of residual aortic regurgitation.

20 to improve the lives of patients with mitral regurgitation.

21 with MitraClip in patients with mitral valve regurgitation.

22 d replacement in patients with native mitral regurgitation.

23 re was no residual moderate or severe aortic regurgitation.

24 tion, adverse hemodynamics, or transvalvular regurgitation.

25 of progressive RV dysfunction and tricuspid regurgitation.

26 less severe and subclinical cases of mitral regurgitation.

27 underestimation of Rvol(VALVE) in severe MV regurgitation.

28 s receiving SE-THV: >= moderate paravalvular regurgitation (15.5% versus 8.3%; relative risk, 1.90 [9

29 d 9 others (1.3%) had new moderate or severe regurgitation 2 grades higher than pre-implantation, for

30 d persistence of GERD symptoms (heartburn or regurgitation 2 or more days in past week) among partici

31 igher incidence of moderate or severe aortic regurgitation (3.5% vs. 0.5%) and pacemaker implantation

32 group had at least mild paravalvular aortic regurgitation (33.3% vs. 6.3%).

33 %]) and moderate or severe prosthetic aortic regurgitation (34 [9%] vs ten [3%]) were more common in

34 VR patients had moderate/severe total aortic regurgitation (8.2% vs. 0.0%, p<0.001) and a new pacemak

35 utable to high residual gradients (14.1%) or regurgitation (8.9%).

36 patients with HF and severe secondary mitral regurgitation, a short-term change in disease-specific h

37 y valves have been used to treat stenosis or regurgitation after prior surgical tricuspid valve (TV)

38 tly, moderate or severe mitral and tricuspid regurgitation also decreased (33.7% vs. 8.6% [p < 0.0001

39 d, 28,655 (0.52%) were diagnosed with mitral regurgitation and a further 1,262 (0.02%) were diagnosed

40 tant clinical outcomes, such as paravalvular regurgitation and conduction abnormalities.

41 en developed, which can predict paravalvular regurgitation and conduction disturbance.

42 ssociated with a higher risk of paravalvular regurgitation and higher in-hospital and 2-year mortalit

43 ng reduced simulation-predicted paravalvular regurgitation and markers of conduction disturbance.

44 lopment of clinically important mitral valve regurgitation and mitral valve stenosis.

45 eas TAVR had higher rates of residual aortic regurgitation and need for pacemaker implantation.

46 Higher rates of prosthetic regurgitation and pacemaker implantation were seen after

47 001) and after further adjustment for mitral regurgitation and pacemaker/defibrillator (HR: 0.35; 95%

48 ocardiography variables (including tricuspid regurgitation and pulmonary regurgitation) and invasive

49 such as the transvalvular flow rate, closure regurgitation and the orifice area, while the difference

50 ne/trace; 1 patient had mild pulmonary valve regurgitation and the remainder had none/trace.

51 luding tricuspid regurgitation and pulmonary regurgitation) and invasive central venous pressure, sys

52 mild MV regurgitation, nine had moderate MV regurgitation, and 11 had severe MV regurgitation, as di

53 female sex, lower ejection fraction, mitral regurgitation, and atrial fibrillation (all P<0.0001).

54 air in patients with severe secondary mitral regurgitation, and implantable cardiac defibrillators in

55 tenosis populations, in patients with aortic regurgitation, and in patients with bicuspid aortic valv

56 ring ventricular systole resulting in mitral regurgitation, and it is associated with sudden cardiac

57 radients, no cases of moderate-severe aortic regurgitation, and none-trace residual aortic regurgitat

58 e, previous acute HF, grade III or IV aortic regurgitation, and pulmonary hypertension both at discha

59 aortic stenosis, moderate and severe aortic regurgitation, and uncorrected coarctation of the aorta.

60 roublesome esophageal symptoms of heartburn, regurgitation, and/or chest pain and inadequate PPI resp

61 More patients had none/trivial aortic regurgitation (AR) (47.5% vs. 33%), and fewer had mild A

62 s hemodynamically-significant chronic aortic regurgitation (AR) are mostly unknown.

63 re, or more than mild intraprosthetic aortic regurgitation (AR) either new or worsening from 3 months

64 2152 patients (41.2% of native VHD), aortic regurgitation (AR) in 279 (5.3%), mitral stenosis (MS) i

65 The natural history of stage B aortic regurgitation (AR) is unknown.

66 ents with hemodynamically significant aortic regurgitation (AR) is unknown.

67 The percentage of moderate or severe aortic regurgitation (AR) was low and not statistically differe

68 outcomes of patients with significant aortic regurgitation (AR).

69 t (TAVR) in patients with pure native aortic regurgitation (AR).

70 aortic valve stenosis (AS) and aortic valve regurgitation (AR).

71 outcomes after surgical treatment of mitral regurgitation are worse if intervention occurs after det

72 fficient, 0.91), more than mild paravalvular regurgitation (area under the receiver operating charact

73 tricular dysfunction, atrioventricular valve regurgitation, arrhythmia, protein-losing enteropathy, a

74 erate MV regurgitation, and 11 had severe MV regurgitation, as diagnosed by using semiquantitative ec

75 d left atrial pressure and stiffness, mitral regurgitation, as well as features of metabolic syndrome

76 3.9%; P=0.01), and moderate or severe aortic regurgitation at 30 days (10% versus 3%; P=0.002) were s

77 sociated with more moderate or severe aortic regurgitation at 30 days and cardiac death at 30 days an

78 ease, heart failure, aortic stenosis, mitral regurgitation, atrial fibrillation, ischemic stroke, per

79 on the basis of the severity of aortic valve regurgitation (AVR) and aortic valve stenosis (AVS).

80 erable over replacement for rheumatic mitral regurgitation but is not available to the vast majority

81 be safe and effective at reducing tricuspid regurgitation by at least one grade.

82 recent percutaneous approach to treat mitral regurgitation by placement of MC in the center of the mi

83 ugust 28, 2013) and had measurable tricuspid regurgitation by spectral Doppler.

84 d preservation for surgical repair of mitral regurgitation caused by prolapse.

85 ricuspid regurgitation, or individual mitral regurgitation characteristics.

86 eart Failure Patients With Functional Mitral Regurgitation [COAPT]; NCT01626079).

87 ealing skirt designed to reduce paravalvular regurgitation compared with XT-TAVR.

88 serositis and severe mitral and aortic valve regurgitation, controlled with adalimumab, tacrolimus, a

89 ling in patients with chronic primary mitral regurgitation (CPMR).

90 eart Failure Patients With Functional Mitral Regurgitation) demonstrated that edge-to-edge transcathe

91 artery pressure assessed from the tricuspid regurgitation derived maximal pressure gradient added to

92 ow-up intervals for TTE assessment of mitral regurgitation, despite risk-adjustment for patient varia

93 lation (AF) complicating degenerative mitral regurgitation (DMR) a debated indication for surgery.

94 largement is frequent in degenerative mitral regurgitation (DMR), but its link to outcomes remains un

95 One patient had recurrent regurgitation due to a paravalvular leak, treated with a

96 mortality in patients with chronic tricuspid regurgitation due to acquired heart disease.

97 ic; however, symptoms may include heartburn, regurgitation, dysphagia, nausea, or vague epigastric pa

98 subgroups of patients with functional mitral regurgitation (eg, disproportionate versus proportionate

99 Overall, tricuspid regurgitation estimated systolic pressure gradient (PG)

100 lower-risk patients with severe mitral valve regurgitation (Evaluation of the Safety and Performance

101 te of moderate-to-severe paravalvular aortic regurgitation (Evolut R/PRO 10.5% versus Sapien 3 4.2%,

102 f chordae tendineae is used, a lower closure regurgitation flow is observed compared to that of a lin

103 167 (14%) had AR + MR (9% functional mitral regurgitation [FMR] [84% nonischemic] and 5% organic mit

104 The mean change in weekly regurgitation frequency score from baseline to week 8 in

105 ent change from baseline to week 8 in weekly regurgitation frequency score.

106 l valve repair (MitraClip) for severe mitral regurgitation from 2007 to 2013 as part of the EVEREST I

107 h heart failure and 3 to 4+ secondary mitral regurgitation from the perspective of the US healthcare

108 the treatment of severe functional tricuspid regurgitation (FTR) due to the awareness of its poor out

109 Functional tricuspid regurgitation (FTR) is common in heart failure with redu

110 as 7 mm Hg, most patients (96.7%) had mitral regurgitation grade <=1 (+) and were in New York Heart A

111 9 patients in sinus rhythm with mitral valve regurgitation (group 2; 32 males; 59+/-12 years).

112 Paravalvular regurgitation >/=moderate was rare in both groups (4.5%

113 Qs can increase the risk of aortic or mitral regurgitation has not been studied.

114 acement therapy, severe preimplant tricuspid regurgitation, history of cardiac surgery, and concomita

115 ; 95% CI: 1.5 to 5.4; p < 0.001), and mitral regurgitation (HR: 5.0; 95% CI: 1.5 to 17.1; p = 0.01).

116 Conclusions In significant tricuspid regurgitation, impaired RV free wall longitudinal strain

117 evice removal was recurrence of heartburn or regurgitation in 5 patients (46%), followed by dysphagia

118 .002) and regurgitation or combined stenosis-regurgitation in 62 (83.8%) and 86 (62.3%) (p = 0.028),

119 ic regurgitation (none-trace and mild aortic regurgitation in 76% and 24% of patients, respectively).

120 s the most common cause of primary tricuspid regurgitation in adults with congenital heart disease, b

121 that Glis1 knockdown causes atrioventricular regurgitation in developing hearts in zebrafish.

122 managed patients with >= moderate tricuspid regurgitation in Europe and North America (n = 1,179) we

123 , weekly, monthly, and overall prevalence of regurgitation in Iranian population was 4.00% (95%CI: 1.

124 r treatment of postoperative pulmonary valve regurgitation in patients with repaired right ventricula

125 Despite the prevalence of mitral regurgitation in the elderly population, however, almost

126 The changes in tricuspid valve regurgitation in the LP group were similar to the change

127 egurgitation, and none-trace residual aortic regurgitation in the majority of patients.

128 Despite the anatomical complexity of mitral regurgitation in the patients in this compassionate use

129 tients with significant functional tricuspid regurgitation, in comparison with tricuspid annular plan

130 e percentage of moderate or severe tricuspid regurgitation increased from baseline to 1 year in SAVR

131 At 1 month after mitral regurgitation induction, pigs developed HF as evidenced

132 One month after mitral regurgitation induction, pigs were randomized to intraco

133 Patients were enrolled in the MIDA (Mitral Regurgitation International Database) registry, which re

134 Severe mitral regurgitation is a common and complex disease that is as

135 Tricuspid regurgitation is a prevalent disease associated with hig

136 Tricuspid regurgitation is associated with increased rates of hear

137 Mitral regurgitation is frequently associated with ventricular

138 Marked tricuspid regurgitation is frequently present in patients with arr

139 n of the papillary muscles, the magnitude of regurgitation is greater than that predicted by LV volum

140 ults show that the risk of aortic and mitral regurgitation is highest with current use followed by re

141 c (TTE) surveillance of patients with mitral regurgitation is indicated to avoid adverse ventricular

142 ejection fraction, and isolated pure aortic regurgitation is now under investigation in clinical tri

143 udy, we demonstrate that Ag released upon DC regurgitation is sufficient to efficiently induce early

144 disproportionate versus proportionate mitral regurgitation) is key to the success of new devices.

145 hickening, excessive leaflet tip motion, and regurgitation jet length >=2 cm, and aortic valve focal

146 d stiffness associations with ECV, tricuspid regurgitation jet velocity (TRV) and exercise abnormalit

147 +/- 0.61 cm(2) and 1.51 +/- 0.57 cm(2); and regurgitation <=mild in 91% and 91%, respectively.

148 Tricuspid regurgitation maximal velocity greater than 2.82 m/s as

149 Tricuspid regurgitation maximal velocity pressure gradient added t

150 Worsening systemic RV function and tricuspid regurgitation may develop after LVOT TPVR.

151 long-term association between SBP and mitral regurgitation (mediator-adjusted HR 1.22; CI 1.20, 1.25;

152 oup had more frequent post-procedural mitral regurgitation moderate or higher (19.4% vs. 6.8%; p = 0.

153 ction fraction, worse post-procedural mitral regurgitation, moderate or severe lung disease, dialysis

154 e but not all patients with secondary mitral regurgitation (MR) and heart failure (HF).

155 t >=10 mm Hg and significant residual mitral regurgitation (MR) as >= moderate.

156 gation has been described for primary mitral regurgitation (MR) caused by mitral valve prolapse.

157 tive for patients with severe primary mitral regurgitation (MR) considered at high or prohibitive sur

158 Severe mitral regurgitation (MR) conveys significant morbidity and mor

159 r has become the standard therapy for mitral regurgitation (MR) due to degenerative diseases, but inf

160 , mitral stenosis (MS) in 234 (4.5%), mitral regurgitation (MR) in 1114 (21.3%, primary in 746 and se

161 tinct pathways can lead to functional mitral regurgitation (MR) in patients with chronic heart failur

162 Unlike secondary mitral regurgitation (MR) in the setting of left ventricular (L

163 Treatment of mitral regurgitation (MR) in the setting of severe mitral annul

164 Mitral regurgitation (MR) is a common valvular heart disease an

165 ve repair (TMVr) for the treatment of mitral regurgitation (MR) is a complex procedure that requires

166 Mitral regurgitation (MR) is a complex valve lesion that can po

167 Mitral regurgitation (MR) is a complex valve lesion that can po

168 Symptomatic mitral regurgitation (MR) is associated with high morbidity and

169 Mitral regurgitation (MR) is the most common type of valvular h

170 symptomatic HF and 3+ to 4+ secondary mitral regurgitation (MR) on maximally-tolerated medical therap

171 Etiology, mechanisms, and survival of mitral regurgitation (MR) plus hemodynamically-significant chro

172 Secondary mitral valve regurgitation (MR) remains a challenging problem in the

173 diographic parameters when evaluating mitral regurgitation (MR) severity.

174 s of AKI in patients with significant mitral regurgitation (MR) undergoing transcatheter valve repair

175 ive patients with severe degenerative mitral regurgitation (MR) were treated with a mitral valve repa

176 restimated in patients with secondary mitral regurgitation (MR) when using LV ejection fraction (EF).

177 ents with either primary or secondary mitral regurgitation (MR) who were at high or prohibitive surgi

178 for patients with symptomatic, severe mitral regurgitation (MR).

179 may affect prognosis in patients with mitral regurgitation (MR).

180 l RV revalvulation for significant pulmonary regurgitation (n=21).

181 Patients with moderate or greater triscuspid regurgitation, New York Heart Association class II or hi

182 Ten patients had mild MV regurgitation, nine had moderate MV regurgitation, and 1

183 g) and the absence of moderate-severe aortic regurgitation (none-trace and mild aortic regurgitation

184 Mitral regurgitation occurs from leaflet coaptation failure tha

185 6 cm(2), with greater than mild paravalvular regurgitation of 1.9%.

186 which develop sclerosing cholangitis due to regurgitation of BA from leaky ducts.

187 nts, resulting in procedural residual mitral regurgitation of grade 2+ or less in 22 (96%) patients.

188 he quantitative assessment of organic mitral regurgitation (OMR).

189 FMR] [84% nonischemic] and 5% organic mitral regurgitation [OMR] [62% degenerative]).

190 MR was defined as >/= mild regurgitation on color Doppler in FHS and from Internati

191 in the assessment of the impact of pulmonary regurgitation on RV size and function.

192 in 12 (16.2%) and 51 (37.0%) (p = 0.002) and regurgitation or combined stenosis-regurgitation in 62 (

193 d by recurrent and troublesome heartburn and regurgitation or GERD-specific complications and affects

194 e was >= moderate occurrence of paravalvular regurgitation or in-hospital mortality, or both.

195 58 (8.5%) had moderate or greater pulmonary regurgitation or maximum Doppler gradients >40 mm Hg.

196 ulmonary hypertension, severity of tricuspid regurgitation, or individual mitral regurgitation charac

197 ocedure, moderate or severe prosthetic valve regurgitation, or prosthetic valve stenosis within 30 da

198 rtic valve function was divided into normal, regurgitation, or stenosis.

199 , severe mitral regurgitation, severe aortic regurgitation, or subaortic stenosis.

200 ntricular valve failure (moderate or greater regurgitation, or valve operation) is a risk factor for

201 (p < 0.001), moderate-to-severe paravalvular regurgitation (p = 0.002), and 30-day mortality (p = 0.0

202 isodes (P = 0.01) but increased frequency of regurgitation (P = 0.03).

203 -severe (3+) or severe (4+) secondary mitral regurgitation, patients treated with transcatheter mitra

204 We mapped their nesting sites and collected regurgitation pellets to recover lemming mandibles, whic

205 dural characteristics (residual mitral valve regurgitation, periprocedural bleeding), site volume, an

206 ated (as distinct from functional) tricuspid regurgitation pose unique challenges.

207 ed tetralogy of Fallot and chronic pulmonary regurgitation (PR).

208 y greater than 2.82 m/s as well as tricuspid regurgitation pressure gradient greater than 32 mm Hg pr

209 indings at discharge (grade III or IV aortic regurgitation, pulmonary hypertension) identified patien

210 severity of coronary artery disease, mitral regurgitation, pulmonary hypertension, right ventricular

211 Moderate/severe and even mild paravalvular regurgitation (PVR) are associated with increased mortal

212 enables more accurate 4D flow MRI-derived MV regurgitation quantification than valve tracking in term

213 2 patients) or severe (6 patients) tricuspid regurgitation recorded at either initial or repeat ablat

214 ith hospital mortality of 2% and with mitral regurgitation reduced to grade </=2 in 87% of patients (

215 (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter Syste

216 tients enrolled in the TRI-REPAIR (TrIcuspid Regurgitation RePAIr With CaRdioband Transcatheter Syste

217 s 69%; P=0.003), and in patients with mitral regurgitation, reproducibility was improved with higher

218 amic abnormalities (more than mild tricuspid regurgitation, residual ventricular septal defect) reduc

219 for severe, moderate, mild, and trace mitral regurgitation, respectively, with 20% of providers deeme

220 ll other symptom scores including heartburn, regurgitation, respiratory symptoms, and pain scores rem

221 e COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic c

222 lve, moderate aortic stenosis, severe mitral regurgitation, severe aortic regurgitation, or subaortic

223 ficacy endpoint was a reduction in tricuspid regurgitation severity by at least one grade at 30 days

224 algorithm was implemented for grading mitral regurgitation severity during the screening process.

225 ression (all p < 0.0001) but not with mitral regurgitation severity or ejection fraction.

226 Regurgitation severity was discordant for seven pulmonar

227 Tricuspid regurgitation severity was reduced by at least one grade

228 Secondary mitral regurgitation (SMR) occurs in the absence of organic mit

229 tative assessment of severe secondary mitral regurgitation (sMR) reflect the lacking link of the sMR

230 with heart failure (HF) and secondary mitral regurgitation (SMR).

231 according to atrial fibrillation and mitral regurgitation status.

232 tcomes, mixed data on SMR and primary mitral regurgitation, studies not clearly reporting the outcome

233 valve consistency, particularly in severe MV regurgitation.Supplemental material is available for thi

234 ndred four patients with degenerative mitral regurgitation surgically amenable to either leaflet rese

235 Regurgitation symptoms also decreased.

236 prevalence of all types GERD, heartburn and regurgitation symptoms by removing a study showed that t

237 significantly lower in patients with mitral regurgitation than in healthy control subjects (P < .001

238 ve dysfunction, men had more frequent aortic regurgitation than women (33.8% versus 22.2%, P<0.001),

239 isk Patients with Severe, Symptomatic Mitral Regurgitation - The Twelve Intrepid TMVR Pilot Study; NC

240 eart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).

241 eart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial]; NCT01626079).

242 tients with significant functional tricuspid regurgitation, timely detection of right ventricular (RV

243 h heart failure and 3 to 4+ secondary mitral regurgitation, TMVr increases life expectancy and qualit

244 sion and volume index, >= moderate tricuspid regurgitation (TR) (7%, 35%, and 53%, respectively), and

245 rsistent or new moderate or severe tricuspid regurgitation (TR) 20.8%, and new atrial fibrillation (A

246 dical treatment options for severe tricuspid regurgitation (TR) are limited, and additional intervent

247 upright invasive exercise testing, tricuspid regurgitation (TR) Doppler estimates and invasive measur

248 Patients with isolated tricuspid regurgitation (TR) in the absence of left-sided valvular

249 Severe tricuspid regurgitation (TR) is associated with high morbidity and

250 Tricuspid regurgitation (TR) is common among adults with corrected

251 The presence of tricuspid regurgitation (TR) may affect prognosis in patients with

252 Functional tricuspid regurgitation (TR) with a structurally normal tricuspid

253 significant (moderate and severe) tricuspid regurgitation (TR), the decision to intervene is influen

254 tricuspid annulus (TA) and reduce tricuspid regurgitation (TR).

255 , 0.89-0.99; P=0.027), and </=mild tricuspid regurgitation (TR; HR, 3.58; 95% CI, 2.04-6.30; P<0.001)

256 eart Failure Patients With Functional Mitral Regurgitation), treatment of heart failure (HF) patients

257 eart Failure Patients with Functional Mitral Regurgitation) trial among patients with heart failure (

258 for Symptomatic Chronic Functional Tricuspid Regurgitation) trial is a prospective, single-arm, multi

259 eart Failure Patients with Functional Mitral Regurgitation) trial, 614 patients with HF with moderate

260 eart Failure Patients with Functional Mitral Regurgitation) trial, transcatheter mitral valve repair

261 eart Failure Patients With Functional Mitral Regurgitation) trial, transcatheter mitral valve repair

262 eart Failure Patients With Functional Mitral Regurgitation) trial.

263 No correlation was found between pulmonary regurgitation velocities and either mean pulmonary arter

264 ed 19%-35%), E/e' ratio (18%-29%), tricuspid regurgitation velocity (27%-41%), and tricuspid annular

265 mitral E velocity, E/e' ratio, and tricuspid regurgitation velocity; and worse right ventricular func

266 o look at the peak jet velocity, the closure regurgitation volume, and the orifice area.

267 Mitral regurgitation was <=2+ in all the cases and mean gradien

268 +/- 5.6 mm Hg, and moderate or severe aortic regurgitation was 1.9% at discharge.

269 Tricuspid valve regurgitation was graded as being more severe in 23 (43%

270 Tricuspid regurgitation was graded using a five-class grading sche

271 r FTR degree compared with trivial tricuspid regurgitation was independently associated with higher m

272 Regurgitation was initiated by removing targeted chordae

273 Rate of mild aortic regurgitation was lower with the repositionable and retr

274 Tricuspid regurgitation was massive (46 mL) (Figs 1-4).

275 Moderate/severe transvalvular regurgitation was noted in 89 patients (3.7%) after TAVR

276 At 12 months, moderate mitral regurgitation was observed in 3 subjects in the leaflet

277 Moderate or greater paravalvular regurgitation was observed in 3.1% of reporting patients

278 An increase in mitral valve regurgitation was observed in 38% of patients ( P=0.006)

279 rate of moderate-severe paravalvular aortic regurgitation was observed in the Evolut R/PRO group at

280 y these proximate causes of secondary mitral regurgitation was only 13% (CI 6.1%, 20%), and accountin

281 Pulmonary regurgitation was recorded in 10 patients (25%).

282 Moderate to severe aortic regurgitation was reduced from 45.1% at pre-TAVR baselin

283 Regurgitation was the main clinically relevant negative

284 alence of >=moderate tricuspid and neoaortic regurgitation was uncommon and did not vary by group or

285 ears]) with significant functional tricuspid regurgitation were divided according to the presence of

286 volume was increased in patients with mitral regurgitation when compared with that in healthy volunte

287 lusions bias related to detectable tricuspid regurgitation, which may limit generalizability of our f

288 ular systolic function and greater tricuspid regurgitation, which persisted at 1 year.

289 imary outcome was incident reports of mitral regurgitation, which were identified from hospital disch

290 r of patients with severe symptomatic mitral regurgitation who are at too high of a risk to undergo o

291 patients with HF and severe secondary mitral regurgitation who remained symptomatic despite maximally

292 d moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite maximally

293 h moderate-severe or severe secondary mitral regurgitation who remained symptomatic despite maximally

294 patients with HF and severe secondary mitral regurgitation who were alive at 1 month, those randomize

295 Among patients with degenerative mitral regurgitation with a flail leaflet referred to mitral su

296 pair and replacement for degenerative mitral regurgitation with a flail leaflet.

297 nstable angina, acute endocarditis, valvular regurgitation with impending heart failure), 10 patients

298 s continuously related to the risk of mitral regurgitation with no evidence of a nadir down to 115 mm

299 h moderate-severe or severe secondary mitral regurgitation with transcatheter mitral valve repair (TM

300 Decision Pathway on the Management of Mitral Regurgitation, with some sections updated and others add